News ReleaseView printer-friendly version
Quidel to Hold Fourth Quarter and Full Year 2011 Financial Results Conference Call on February 29, 2012
SAN DIEGO, CA, Feb 02, 2012 (MARKETWIRE via COMTEX) -- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, will release fourth quarter and full year 2011 financial results after market close on Wednesday, February 29, 2012.
Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss those results and to answer questions. During the conference call, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previously disclosed.
To participate in the live call by telephone from the U.S., dial 866-383-8008, or from outside the U.S. dial 617-597-5341, and enter the pass code 75563656.
A live webcast of the call can be accessed at http://www.quidel.com, and the Web site replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on February 29th by dialing 888-286-8010 from the U.S., or 617-801-6888 for international callers, and entering pass code 17782358.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue(R), D3(R) Direct Detection and Thyretain(TM) leading brand names, as well as under the new Sofia(TM) and Quidel Molecular(TM) brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions,including influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.
Chief Financial Officer
Media and Investors Contact: